Max represents private and public companies in transactional and general corporate matters, including entity formation, corporate governance, mergers & acquisitions, private financings, public offerings, and SEC reporting and compliance.
Hengrui Pharma and Braveheart Bio Enter Into Exclusive License Agreement
September 5, 2025
Cooley advised Hengrui Pharma, a global pharmaceutical company, on its exclusive license agreement with Braveheart Bio for HRS-1893, a small-molecule inhibitor of cardiac myosin independently developed by Hengrui Pharma with best-in-class potential.
Enlaza Therapeutics Announces Strategic Collaboration With Vertex Pharmaceuticals
September 2, 2025
Cooley advised Enlaza Therapeutics, the first covalent biologics platform company, on its multi-target drug discovery collaboration with Vertex Pharmaceuticals, to utilize Enlaza’s proprietary War-Lock technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.
Structure Therapeutics Announces Upsized $547.4 Million Public Offering
June 7, 2024
Cooley advised Structure Therapeutics (Nasdaq: GPCR), a global, clinical-stage biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, on its upsized $547.4 million underwritten public offering.
